- ￥4500
- GeneTex
- 美国
- GTX75811
- 2025年07月14日
- FACS
- Mouse
- Rat
企业认证
相关产品推荐更多 >
![ZER1 antibody [C2C3], C-term](https://img1.dxycdn.com/2023/0711/255/2344116916935858761-14.jpg!wh200)
![VDP / p115 antibody [C3], C-term](https://img1.dxycdn.com/2023/0516/895/8887749495766728561-14.jpg!wh200)
![eIF2 alpha antibody [1H1]](https://img1.dxycdn.com/2023/0711/451/6106825198874858761-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Purified rCTLA-4hIg fusion protein.
- 亚型：
IgG1
- 形态：
Liquid
- 保存条件：
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. Protect from light.
- 克隆性：
Monoclonal
- 标记物：
PE
- 适应物种：
Rat
- 保质期：
12 months from the shipping date of the product.
- 抗原来源：
Rat
- 目录编号：
GTX75811
- 级别：
Primary Antibodies
- 库存：
Available
- 供应商：
GeneTex
- 宿主：
Mouse
- 应用范围：
FACS
- 浓度：
0.1 mg/ml (Please refer to the vial label for the specific concentration.)
- 靶点：
CTLA4
- 抗体英文名：
CTLA4 antibody [WKH203] (PE)
- 抗体名：
CTLA4 抗体 [WKH203] (PE)
- 规格：
1 ml
Staining of rat CD152 transfected cell line using Mouse anti Rat CD152 (GTX75808) following permeabilisation with Leucoperm
Staining of rat CD152 transfected cell line using Mouse anti Rat CD152 following permeabilisation with Leucoperm
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Western Blotting with Horseradish Pe
7.5, 100mM NaCl, 0.1% Tween 20). 2.Incubate the blot for 30 minutes at 37℃, 1 hour at room temperature, or overnight at 4℃. INCUBATION WITH HORSERADISH PEROXIDASE CONJUGATED ANTIBODY NOTE: THE INCLUSION OF SODIUM AZIDE IS TO BE AVOIDED IN ALL STEPS
T-cell dependent antigen specific in situ staining (Pe)
if you have them). Let them dry approx 1 hour in a dry atmosphere at RT. Antibodies (anti-Pe) in the sections degrade more rapidly than tissue antigens. Proceed with staining within 24 hours or freeze the slides. Antigen-specific staining: (Pe staining of Pe
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
